World · India Bureau
Biocon wins FDA nod for fifth cancer biosimilar Pebrilzo
Indian biotech firm Biocon has secured US regulatory approval for Pebrilzo, expanding its oncology biosimilar portfolio. The company has also reached a global settlement with Genentech permitting market entry in 2028.
LSN India ·

Biocon Limited has obtained approval from the United States Food and Drug Administration for Pebrilzo, marking the company's fifth cancer biosimilar to reach the American market. The Bangalore-headquartered biopharmaceutical firm disclosed that the regulatory clearance strengthens its position in the competitive oncology biosimilars segment, which has emerged as a key growth driver for Indian drug manufacturers.
The company simultaneously announced a global settlement and licensing agreement with Genentech, the originator of the reference biologic. Under the terms of the arrangement, Biocon secured the earliest permissible launch date of 2028 in the United States, providing a defined timeline for commercialization.
Biosimilars represent a significant opportunity for Indian pharmaceutical companies to expand into high-value segments of the global market. Biocon's growing portfolio in oncology biosimilars demonstrates the sector's capability to develop complex biological therapeutics that meet stringent international regulatory standards. The Pebrilzo approval underscores the company's investment in research and development infrastructure and its commitment to making advanced cancer treatments more accessible through competitively priced alternatives.
The settlement agreement with Genentech is expected to facilitate a smoother regulatory pathway and market entry strategy for Biocon in the lucrative US pharmaceutical market, where biosimilars continue to gain acceptance among healthcare providers and payers seeking cost-effective treatment options.